Biocon Limited BIOCON
NSE · Hindistan · Sağlık Teknolojisi
INR 370,70+0,40 (+%0,11)
Piyasa kapalı· · INR · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Piyasa kapalı· · INR · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Temettüler dahil toplam getiri.
Fiyatın 50 ve 200 günlük hareketli ortalamalara göre konumu.
Makkler Adil Değer, finansal sağlık skoru, analist görüşü, benzer şirketler ve MakklerAI.
Biocon Biologics Limited, a wholly-owned subsidiary of Biocon Limited (BSE: 532523) (NSE: BIOCON), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the granting of a marketing authorisation to its Pertuzumab biosimilar as 420 mg concentrate solution for infusion, under the brand name Pebrilzo®, for the treatment of HER2–positive breast cancer across multiple disease stages.
Biocon’s updated analyst model now points to a fair value of ₹446.89, compared with the earlier estimate of ₹429.67, which translates to a roughly 4% uplift in the price target. Recent analyst commentary links this higher fair value to views on Biocon’s execution quality, earnings visibility, and how the current risk profile compares with that new target. As you read on, you will see how this revised price target fits into the evolving narrative around the stock and what it may mean for your...
Tariff threats from the US are colliding with India’s export surge, and that clash is putting a fresh spotlight on large-cap exporters with heavy US exposure. Some stocks could see pressure if trade friction bites. Others may benefit as supply chains and free trade deals are rewired. This article breaks down three such stocks from the screener and how this news could matter for your portfolio decisions. The three stocks covered below are just a sample from this theme, and the full screen...
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.